Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 8/20 | 0.66 |
| ▸ | S1PR4 | O95977 | 7/20 | 0.66 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.66 |
| ▸ | TNNC1 | P63316 | 5/20 | 0.66 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.66 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.66 |
| ▸ | GPR183 | P32249 | 1/20 | 0.66 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.66 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.59 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.57 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.56 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | RARB | P10826 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2632242 | 0.87 | S1PR1 (0.67) | S1PR1S1PR4S1PR3TNNC1S1PR5 | |
| SCHEMBL13932767 | 0.87 | S1PR1 (0.67) | S1PR1S1PR4S1PR3TNNC1S1PR5 | |
| SCHEMBL13953201 | 0.85 | S1PR1 (0.48) | S1PR1S1PR4S1PR3TNNC1S1PR5 | |
| SCHEMBL2632241 | 0.85 | S1PR1 (0.61) | S1PR1S1PR4S1PR3TNNC1S1PR5 | |
| SCHEMBL13932769 | 0.83 | S1PR1 (0.62) | S1PR1S1PR4S1PR3TNNC1S1PR5 | |
| SCHEMBL2622475 | 0.81 | S1PR1 (0.42) | S1PR1S1PR4S1PR3TNNC1S1PR5 | |
| SCHEMBL2622478 | 0.81 | ARG1 (0.47) | S1PR1S1PR4S1PR3TNNC1S1PR5 | |
| Fingolimod SCHEMBL7445 | 0.80 | S1PR1 (1.00) | S1PR1S1PR4S1PR3TNNC1S1PR5 | |
| SCHEMBL3390328 | 0.80 | S1PR1 (1.00) | S1PR1S1PR4S1PR3TNNC1S1PR5 | |
| SCHEMBL3394797 | 0.80 | S1PR1 (1.00) | S1PR1S1PR4S1PR3TNNC1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042772-A1 | COMPOUNDS AND METHODS OF TREATING INSULIN RESISTANCE AND CARDIOMYOPATHY | TRANSITION THERAPEUTICS INC. (CA) | 2009-02-12 | — | — | US | disclosed |
| US-20080139455-A1 | COMPOUNDS AND METHODS OF TREATING METABOLIC SYNDROME AND INFLAMMATION | FORBES MEDI-TECH (RESEARCH), INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080096799-A1 | COMPOUNDS FOR AND METHODS OF TREATING INSULIN RESISTANCE AND INFLAMMATION | FORBES MEDI-TECH (RESEARCH), INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20070135450-A1 | Compounds and Methods of Treating Insulin Resistance and Cardiomyopathy | FORBES MEDI-TECH (RESEARCH), INC. (US) | 2007-06-14 | — | — | US | disclosed |
| US-7189748-B2 | Compounds and methods for treating insulin resistance and cardiomyopathy | FORBES MEDI-TECH (RESEARCH), INC. (US) | 2007-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096799-A1 | COMPOUNDS FOR AND METHODS OF TREATING INSULIN RESISTANCE AND INFLAMMATION | PNLIP, CPT1A, CPT1B | S1PR1 61/4885S1PR4 204/4885S1PR3 126/4885 |
| US-20090042772-A1 | COMPOUNDS AND METHODS OF TREATING INSULIN RESISTANCE AND CARDIOMYOPATHY | CPT1A, CPT1B, PNLIP | S1PR1 161/4885S1PR4 391/4885S1PR3 282/4885 |
| US-20080139455-A1 | COMPOUNDS AND METHODS OF TREATING METABOLIC SYNDROME AND INFLAMMATION | PNLIP, CPT1A, CPT1B | S1PR1 40/4885S1PR4 171/4885S1PR3 92/4885 |
| US-20070135450-A1 | Compounds and Methods of Treating Insulin Resistance and Cardiomyopathy | CPT1A, CPT1B, PNLIP | S1PR1 161/4885S1PR4 391/4885S1PR3 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.